— Positive DSMB review of first patient cohort in UshStat® Phase I/IIa Study —— Further encouraging data from RetinoStat® and StarGen™ clinical studies — Oxford, UK – 20 November 2012: Oxford BioMedica plc…
Oxford, UK 14 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1…
– Leading intellectual property position further strengthened — Oxford, UK – 9 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that…
Oxford, UK – 10 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase…
— Appointment of New Non-Executive Director — Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces the appointment…
Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, has signed a master services…
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay file. Oxford, UK – 31 August 2012: Oxford BioMedica…
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay file. Oxford, UK – 31 August 2012: Oxford BioMedica…
— 14th Annual Healthcare Conference — Oxford, UK – 29 August 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that John…
— Treatment of final RetinoStat® patient cohort underway — Oxford, UK – 08 August 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, and its…
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED…
— Award of US$125,000 will support a second clinical site in Paris, France — Oxford, UK – 23 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the…